Barclays
PTLA

Barclays’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Barclays’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,100
Closed -$21K – 7512
2018
Q4 		$21K Hold
1,100
– – ﹤0.01% 5888
2018
Q3 		$29K Sell
1,100
-600
-35% -$19.6K ﹤0.01% 6334
2018
Q2 		$64K Sell
1,700
-547,200
-100% -$20.9M ﹤0.01% 5515
2018
Q1 		$17.9M Buy
548,900
+539,100
+5,501% +$23.7M 0.01% 906
2017
Q4 		$477K Buy
9,800
+5,900
+151% +$298K ﹤0.01% 3880
2017
Q3 		$211K Sell
3,900
-300
-7% -$17.6K ﹤0.01% 4381
2017
Q2 		$236K Sell
4,200
-8,600
-67% -$344K ﹤0.01% 4230
2017
Q1 		$501K Buy
12,800
+7,400
+137% +$236K ﹤0.01% 3400
2016
Q4 		$121K Buy
+5,400
New +$105K ﹤0.01% 4616
2016
Q1 		– Sell
-40,000
Closed -$2.04M – 6579
2015
Q4 		$2.04M Buy
+40,000
New +$1.94M ﹤0.01% 2017

Barclays's PTLA Position: Q3 2020 in Review

Barclays sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 1,306,377 shares — an estimated $23.5M sold.

Barclays first reported a position in PTLA in Q2 2013 and held it in 29 quarters. The position peaked at $23.5M in Q2 2020. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.

  • Barclays reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Barclays sold 1,306,377 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $23.5M.
  • Barclays first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and held it in 29 quarters.
  • Barclays's Portola Pharmaceuticals, Inc. position peaked at $23.5M in Q2 2020.
  • 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.

Based on Barclays's 13F filing for Q3 2020, filed 12 Nov 2020.